Helix Biopharma (OTCMKTS:HBPCF) is a clinical‐stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel immunotherapeutic drug candidates for oncology and infectious diseases. The company leverages a proprietary targeted radiotherapy platform that employs a rhenium‐188 radioisotope generator to deliver cytotoxic payloads directly to tumor sites, while minimizing exposure to healthy tissue. In parallel, Helix is advancing immunomodulatory agents designed to stimulate the body’s natural defenses against viral and bacterial pathogens.
In its oncology pipeline, Helix Biopharma is developing radioimmunotherapy constructs aimed at a variety of solid tumors, including colorectal and pancreatic cancers. Preclinical studies have demonstrated promising tumor‐targeting capabilities and a favorable safety profile, supporting the progression of lead assets toward Phase I/II clinical trials. On the infectious disease front, the company is exploring broad‐spectrum immunotherapy candidates targeting emerging viral threats, with ongoing research into modes of action that enhance both innate and adaptive immune responses.
Founded as a spin‐out from research initiatives in Canada, Helix Biopharma maintains its headquarters in Montreal and conducts R&D activities across North America and Europe through strategic partnerships with academic institutions and contract research organizations. The company’s historical milestones include the successful in‐licensing of its radioisotope generator technology, the establishment of GMP manufacturing capabilities for radiopharmaceuticals, and the initiation of several proof‐of‐concept studies that underscore the versatility of its therapeutic platforms.
Helix Biopharma is led by President and CEO James R. Cowan, whose background in clinical oncology and translational research guides the company’s strategic direction. The senior leadership team comprises experts in radiochemistry, clinical development, and regulatory affairs, ensuring a balanced approach to both innovative science and rigorous trial design. With a focus on advancing multiple programs through clinical and regulatory milestones, Helix Biopharma continues to build a pipeline of differentiated immunotherapies aimed at addressing unmet medical needs.
